Vnitr Lek 2018, 64(10):949-952 | DOI: 10.36290/vnl.2018.132

Fatty pancreas disease: clinical impact

Martin Blaho1,*, Petr Dítě1, Lumír Kunovský2,3, Arnošt Martínek1
1 Gastroenterologické oddělení Interní kliniky LF OU a FN Ostrava
2 Interní gastroenterologická klinika LF MU a FN Brno, pracoviště Bohunice
3 Chirurgická klinika LF MU a FN Brno, pracoviště Bohunice

Pancreatic steatosis is the name for a state characterized by an increased accumulation of fat in the pancreas. It is most frequently due to obesity and the metabolic syndrome, other etiological factors may include some congenital syndromes, toxic substances or viral diseases. Diagnostics is based on non-invasive imaging methods. The most accessible is abdominal ultrasound, also endoscopic ultrasound, computed tomography or magnetic resonance imaging can be used. In clinical practice, pancreatic steatosis is in particular significant because of its close association with type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular diseases. The disorder may aggravate the burden of acute pancreatitis, examined is its relationship to pancreatic cancer. Significant are also surgical reports on complications after pancreatic surgeries on individuals with pancreatic steatosis.

Keywords: acute pancreatitis; dyslipidemia; fatty pancreas; non-alcoholic fatty pancreas disease; non-alcoholic steatopancreatitis; obesity; pancreatic carcinoma

Received: May 6, 2018; Accepted: May 30, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blaho M, Dítě P, Kunovský L, Martínek A. Fatty pancreas disease: clinical impact. Vnitr Lek. 2018;64(10):949-952. doi: 10.36290/vnl.2018.132.
Download citation

References

  1. Alberti KG,Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120(16): 1640-1645. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644>. Go to original source... Go to PubMed...
  2. Hůlek P, Dreslerová I. Steatóza a steatopankreatitida u diabetika. Vnitř Lék 2011; 57(4): 364-367. Go to PubMed...
  3. Sodhi KS,Thapa BR, Khandelwal S et al. Pancreatic lipomatosis in an infant with cystic fibrosis. Pediatr Radiol 2005; 35(11): 1157-1158. Dostupné z DOI: <http://dx.doi.org/10.1007/s00247-005-1520-9>. Go to original source... Go to PubMed...
  4. Raeder H, Haldorsen IS, Ersland L et al. Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes 2007; 56(2): 444-449. Dostupné z DOI: <http://dx.doi.org/10.2337/db06-0859>. Go to original source... Go to PubMed...
  5. Mathur A, Marine M, Lu D et al. Nonalcoholic fatty pancreas disease. HPB (Oxford) 2007; 9(4) 312-318. Dostupné z DOI: <http://dx.doi.org/10.1080/13651820701504157>. Go to original source... Go to PubMed...
  6. Makay O, Kazimi M, Aydin U et al. Fat replacement of the malignant pancreatic tissue after neoadjuvant therapy. Int J Clin Oncol 2010; 15(1): 88-92. Dostupné z DOI: <http://dx.doi.org/10.1007/s10147-009-0001-9>. Go to original source... Go to PubMed...
  7. Smits MM, Van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011; 8(3): 169. Dostupné z DOI: <http://dx.doi.org/10.1038/nrgastro.2011.4>. Go to original source... Go to PubMed...
  8. Blaho M, Dítě P. Metabolic syndrome and non-alcoholic fatty pancreas disease (NAFPD). Pancreatology 2018; 18(4 Suppl): S108. Go to original source...
  9. Ambesh P, Lal H. Pancreatic lipomatosis: complete replacement of pancreas by fat. J Clin Diagn Res 2015; 9(10): OL01. Dostupné z DOI: <http://dx.doi.org/10.7860/JCDR/2015/15085.6653>. Go to original source... Go to PubMed...
  10. Wong VW, Wong GL, Yeung DK et al. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol 2014; 109(4): 589-597. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2014.1>. Go to original source... Go to PubMed...
  11. Schafer JH. The normal weight of the pancreas in the adult human being: a biometric study. The Anatomical Record 1926; 32(2): 119-132. Dostupné z DOI: <https://doi.org/10.1002/ar.1090320204>. Go to original source...
  12. Ogilvie RF. The islands of Langerhans in 19 cases of obesity. J Pathol 1933; 37(3): 473-481. Dostupné z DOI: <https://doi.org/10.1002/path.1700370314>. Go to original source...
  13. Zhang X, Cui Y, Fang L et al. Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in rats. Pancreas 2008; 37: e31-e38. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3181744b50>. Go to original source... Go to PubMed...
  14. Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol 2013; 12: 77. Dostupné z DOI: <http://dx.doi.org/10.1186/1475-2840-12-77>. Go to original source... Go to PubMed...
  15. Uygun A, Kadayifci A, Demirci H et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med 2015; 26(1): 37-41. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2014.11.007>. Go to original source... Go to PubMed...
  16. Zhou J, Li ML, Zhang DD et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology 2016; 16(4): 578-583. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pan.2016.03.008>. Go to original source... Go to PubMed...
  17. Rossi AP et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obesity 2011; 19(9): 1747-1754. Go to original source... Go to PubMed...
  18. Sepe PS, Ohri A, Sanaka S et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc 2011; 73(5): 987-993. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gie.2011.01.015>. Go to original source... Go to PubMed...
  19. Mirrakhimov AE. Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea? Cardiovasc Diabetol 2014; 13: 29. Dostupné z DOI: <http://dx.doi.org/10.1186/1475-2840-13-29>. Go to original source... Go to PubMed...
  20. Bojková M, Dítě P. Obezita ve vztahu k onemocnění pankreatu. Interní Med 2016; 18(4): 176-178. Go to original source...
  21. Acharya Ch, Navina S, Singh VP. Role of pancreatic fat in the outcomes of pancreatitis. Pancreatology 2014; 14(5): 403-408. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pan.2014.06.004>. Go to original source... Go to PubMed...
  22. Vašura A, Blaho M, Dítě P et al. Adiponektin u nemocných s metabolickým syndromem a chorobami jater, žlučových cest a pankreatu. Vnitř Lék 2017; 63(12): 945-948. Go to original source...
  23. Ou HY, Wang CY, Yang Y Cet al. The association between nonalcoholic fatty pancreas disease and diabetes. PloS One 2013; 8(5): e62561. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0062561>. Go to original source... Go to PubMed...
  24. Yu TY, Wang CY. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig 2017; 8(6): 735-747. Dostupné z DOI: <http://dx.doi.org/10.1111/jdi.12665>. Go to original source... Go to PubMed...
  25. Tushuizen ME, Bunck MC, Pouwels PJ et al. Pancreatic fat content and β-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 30(11): 2916-2921. Dostupné z DOI: <http://dx.doi.org/10.2337/dc07-0326>. Erratum in Diabetes Care 2008; 31(4): 835. Go to original source... Go to PubMed...
  26. van der Zijl NJ, Goossens GH, Moors CC et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011; 96(2) :459-467. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010-1722>. Go to original source... Go to PubMed...
  27. Tomita Y, Azuma K, Nonaka Y et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas 2014; 43(7): 1032-1041. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0000000000000159>. Go to original source... Go to PubMed...
  28. Lesmana CRA, Gani RA, Lesmana LA. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. JGH Open 2018; 2(1): 4-7. Dostupné z DOI: <https://doi.org/10.1002/jgh3.12032>. Go to original source... Go to PubMed...
  29. Tranchart H et al. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. Ann Surg 2012; 256(1): 139-145. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0b013e318256c32c>. Go to original source... Go to PubMed...
  30. Gaujoux S et al. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol 2012; 19(9): 2908-2916. Dostupné z DOI: <http://dx.doi.org/10.1245/s10434-012-2301-y>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.